Cargando…

Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis

BACKGROUND: Neoadjuvant chemotherapy (NAC) increases breast conservation rates in patients with resectable breast cancer at the associated cost of higher locoregional recurrence rates; however, the magnitude of the survival benefits of NAC for these patients remains undefined. Therefore, we aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yan, Shi, Xiu-E, Tian, Jin-Hui, Yang, Xu-Juan, Wang, Yong-Feng, Yang, Ke-Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976345/
https://www.ncbi.nlm.nih.gov/pubmed/29768327
http://dx.doi.org/10.1097/MD.0000000000010634
_version_ 1783327162677329920
author Chen, Yan
Shi, Xiu-E
Tian, Jin-Hui
Yang, Xu-Juan
Wang, Yong-Feng
Yang, Ke-Hu
author_facet Chen, Yan
Shi, Xiu-E
Tian, Jin-Hui
Yang, Xu-Juan
Wang, Yong-Feng
Yang, Ke-Hu
author_sort Chen, Yan
collection PubMed
description BACKGROUND: Neoadjuvant chemotherapy (NAC) increases breast conservation rates in patients with resectable breast cancer at the associated cost of higher locoregional recurrence rates; however, the magnitude of the survival benefits of NAC for these patients remains undefined. Therefore, we aimed to clarify the survival benefit of NAC versus postoperative chemotherapy by conducting an updated meta-analysis of randomized clinical trials (RCTs). METHODS: The authors searched the Cochrane Library, PubMed, Embase, Web of Science, Chinese biomedical literature database, and Chinese Scientific Journals full-text database from their inception to December 2016. The authors identified relevant RCTs that compared NAC with postoperative chemotherapy in the treatment of operable breast cancer. The main endpoints were overall survival (OS) and recurrence-free survival (RFS). RESULTS: : A total of 21 citations representing 16 unique studies were eligible. There were 787 deaths among 2794 patients assigned to NAC groups and 816 deaths among 2799 patients assigned to adjuvant chemotherapy groups. A meta-analysis of data indicated that there was no significant benefit in terms of OS ([hazard ratio [HR] = 1.03, 95% confidence interval [CI]: 0.94–1.13, P = .51) and RFS (HR = 1.01, 95% CI: 0.93–1.10, P = .80) between the NAC and postoperative chemotherapy groups. The pooled HR estimate for OS was not influenced by NAC cycles, the total number of chemotherapy cycles, administration of tamoxifen, administration of adjuvant chemotherapy, or type of NAC regimen. Subgroup analysis showed that the pooled HR estimate for RFS was influenced by anthracycline-containing regimens. Patients with a pathological complete response had superior survival outcomes compared with patients who had residual disease. CONCLUSION: The survival benefits for patients with operable breast cancer who received either NAC or adjuvant chemotherapy based on anthracycline regimens were comparable.
format Online
Article
Text
id pubmed-5976345
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-59763452018-06-05 Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis Chen, Yan Shi, Xiu-E Tian, Jin-Hui Yang, Xu-Juan Wang, Yong-Feng Yang, Ke-Hu Medicine (Baltimore) Research Article BACKGROUND: Neoadjuvant chemotherapy (NAC) increases breast conservation rates in patients with resectable breast cancer at the associated cost of higher locoregional recurrence rates; however, the magnitude of the survival benefits of NAC for these patients remains undefined. Therefore, we aimed to clarify the survival benefit of NAC versus postoperative chemotherapy by conducting an updated meta-analysis of randomized clinical trials (RCTs). METHODS: The authors searched the Cochrane Library, PubMed, Embase, Web of Science, Chinese biomedical literature database, and Chinese Scientific Journals full-text database from their inception to December 2016. The authors identified relevant RCTs that compared NAC with postoperative chemotherapy in the treatment of operable breast cancer. The main endpoints were overall survival (OS) and recurrence-free survival (RFS). RESULTS: : A total of 21 citations representing 16 unique studies were eligible. There were 787 deaths among 2794 patients assigned to NAC groups and 816 deaths among 2799 patients assigned to adjuvant chemotherapy groups. A meta-analysis of data indicated that there was no significant benefit in terms of OS ([hazard ratio [HR] = 1.03, 95% confidence interval [CI]: 0.94–1.13, P = .51) and RFS (HR = 1.01, 95% CI: 0.93–1.10, P = .80) between the NAC and postoperative chemotherapy groups. The pooled HR estimate for OS was not influenced by NAC cycles, the total number of chemotherapy cycles, administration of tamoxifen, administration of adjuvant chemotherapy, or type of NAC regimen. Subgroup analysis showed that the pooled HR estimate for RFS was influenced by anthracycline-containing regimens. Patients with a pathological complete response had superior survival outcomes compared with patients who had residual disease. CONCLUSION: The survival benefits for patients with operable breast cancer who received either NAC or adjuvant chemotherapy based on anthracycline regimens were comparable. Wolters Kluwer Health 2018-05-18 /pmc/articles/PMC5976345/ /pubmed/29768327 http://dx.doi.org/10.1097/MD.0000000000010634 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Chen, Yan
Shi, Xiu-E
Tian, Jin-Hui
Yang, Xu-Juan
Wang, Yong-Feng
Yang, Ke-Hu
Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis
title Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis
title_full Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis
title_fullStr Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis
title_full_unstemmed Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis
title_short Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis
title_sort survival benefit of neoadjuvant chemotherapy for resectable breast cancer: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976345/
https://www.ncbi.nlm.nih.gov/pubmed/29768327
http://dx.doi.org/10.1097/MD.0000000000010634
work_keys_str_mv AT chenyan survivalbenefitofneoadjuvantchemotherapyforresectablebreastcancerametaanalysis
AT shixiue survivalbenefitofneoadjuvantchemotherapyforresectablebreastcancerametaanalysis
AT tianjinhui survivalbenefitofneoadjuvantchemotherapyforresectablebreastcancerametaanalysis
AT yangxujuan survivalbenefitofneoadjuvantchemotherapyforresectablebreastcancerametaanalysis
AT wangyongfeng survivalbenefitofneoadjuvantchemotherapyforresectablebreastcancerametaanalysis
AT yangkehu survivalbenefitofneoadjuvantchemotherapyforresectablebreastcancerametaanalysis